These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26056025)

  • 1. Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Anastasilakis AD; Kountouras J; Makras P; Papatheodorou A; Kokkoris P; Sakellariou GT; Terpos E
    J Bone Miner Metab; 2016 Jul; 34(4):447-56. PubMed ID: 26056025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 3.  Vaspin, resistin, retinol-binding protein-4, interleukin-1α and interleukin-6 in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Polymerou V; Papadimitriou KG; Zavos C; Katsinelos P
    Ann Hepatol; 2016; 15(5):705-14. PubMed ID: 27493109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis.
    Sun W; Tian L; Jiang L; Zhang S; Zhou M; Zhu J; Xue J
    Clin Rheumatol; 2019 Apr; 38(4):989-995. PubMed ID: 30443790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes.
    Mantovani A; Sani E; Fassio A; Colecchia A; Viapiana O; Gatti D; Idolazzi L; Rossini M; Salvagno G; Lippi G; Zoppini G; Byrne CD; Bonora E; Targher G
    Diabetes Metab; 2019 Sep; 45(4):347-355. PubMed ID: 30315891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke.
    He XW; Wang E; Bao YY; Wang F; Zhu M; Hu XF; Jin XP
    Atherosclerosis; 2016 Oct; 253():22-28. PubMed ID: 27573735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin and Dkk-1 in patients with ankylosing spondylitis.
    Ustun N; Tok F; Kalyoncu U; Motor S; Yuksel R; Yagiz AE; Guler H; Turhanoglu AD
    Acta Reumatol Port; 2014; 39(2):146-51. PubMed ID: 25111416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
    Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
    Göbel A; Kuhlmann JD; Link T; Wimberger P; Browne AJ; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2017 Aug; 164(3):737-743. PubMed ID: 28526959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between serum and synovial fluid Dickkopf-1 levels with radiographic severity in primary knee osteoarthritis patients.
    Theologis T; Efstathopoulos N; Nikolaou V; Charikopoulos I; Papapavlos I; Kokkoris P; Papatheodorou A; Nasiri-Ansari N; Kassi E
    Clin Rheumatol; 2017 Aug; 36(8):1865-1872. PubMed ID: 28451870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study.
    Liakou CG; Mastorakos G; Makris K; Fatouros IG; Avloniti A; Marketos H; Antoniou JD; Galanos A; Dontas I; Rizos D; Tournis S
    Endocrine; 2016 Nov; 54(2):543-551. PubMed ID: 27601021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease.
    Polyzos SA; Kountouras J; Mavrouli M; Katsinelos P; Doulberis M; Gavana E; Duntas L
    Exp Clin Endocrinol Diabetes; 2019 Oct; 127(9):598-602. PubMed ID: 30625508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine.
    Kashii M; Matuso Y; Sugiura T; Fujimori T; Nagamoto Y; Makino T; Kaito T; Ebina K; Iwasaki M; Yoshikawa H
    J Bone Miner Metab; 2016 May; 34(3):315-24. PubMed ID: 26040409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.
    Wanby P; Nobin R; Von SP; Brudin L; Carlsson M
    J Endocrinol Invest; 2016 Aug; 39(8):855-63. PubMed ID: 26850415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of Dkk-1, sclerostin and VEGF in patients with ankylosing spondylitis and their association with smoking, and clinical, inflammatory and radiographic parameters.
    Sakellariou GT; Iliopoulos A; Konsta M; Kenanidis E; Potoupnis M; Tsiridis E; Gavana E; Sayegh FE
    Joint Bone Spine; 2017 May; 84(3):309-315. PubMed ID: 27369645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum homocysteine levels in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Patsiaoura K; Katsiki E; Zafeiriadou E; Deretzi G; Zavos C; Gavalas E; Katsinelos P; Mane V; Slavakis A
    Ann Hepatol; 2012; 11(1):68-76. PubMed ID: 22166563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications.
    Yang CY; Chang ZF; Chau YP; Chen A; Yang WC; Yang AH; Lee OK
    Nephrol Dial Transplant; 2015 Aug; 30(8):1356-63. PubMed ID: 25817223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.
    Cejka D; Jäger-Lansky A; Kieweg H; Weber M; Bieglmayer C; Haider DG; Diarra D; Patsch JM; Kainberger F; Bohle B; Haas M
    Nephrol Dial Transplant; 2012 Jan; 27(1):226-30. PubMed ID: 21613383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.